Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward M Vital

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
Science Translational Medicine|April 27, 2022
Keratinocytes: From passive targets to active mediators of systemic autoimmunityAntonios Psarras, Edward M Vital
Best Practice & Research. Clinical Rheumatology|August 24, 2023
Musculoskeletal manifestations of systemic lupus erythematosusAnastasiia Shumilova, Edward M Vital
Therapeutics and Clinical Risk Management|March 25, 2008
Abatacept in the treatment of rheumatoid arthritisEdward M Vital, Paul Emery
Drugs of Today (Barcelona, Spain : 1998)|March 17, 2006
AbataceptEdward M Vital, Paul Emery
Journal of Autoimmunity|May 27, 2008
The development of targeted therapies in rheumatoid arthritisEdward M Vital, Paul Emery
The New England Journal of Medicine|October 19, 2022
Anti-BDCA2 Antibody for Cutaneous Lupus ErythematosusAntonios Psarras, Edward M Vital
Nature Reviews. Rheumatology|September 13, 2022
Emerging concepts of type I interferons in SLE pathogenesis and therapyAntonios Psarras, Miriam Wittmann, Edward M Vital
Current Opinion in Rheumatology|June 30, 2017
Musculoskeletal manifestations of systemic lupus erythmatosusKhaled Mahmoud, Ahmed Zayat, Edward M Vital
Rheumatology (Oxford, England)|April 12, 2012
Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosusEdward M Vital, Shouvik Dass, Paul Emery
Expert Opinion on Pharmacotherapy|December 8, 2006
Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritisShouvik Dass, Edward M Vital, Paul Emery
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
Science Translational Medicine|April 27, 2022
Keratinocytes: From passive targets to active mediators of systemic autoimmunityAntonios Psarras, Edward M Vital
Best Practice & Research. Clinical Rheumatology|August 24, 2023
Musculoskeletal manifestations of systemic lupus erythematosusAnastasiia Shumilova, Edward M Vital
Therapeutics and Clinical Risk Management|March 25, 2008
Abatacept in the treatment of rheumatoid arthritisEdward M Vital, Paul Emery
Drugs of Today (Barcelona, Spain : 1998)|March 17, 2006
AbataceptEdward M Vital, Paul Emery
Journal of Autoimmunity|May 27, 2008
The development of targeted therapies in rheumatoid arthritisEdward M Vital, Paul Emery
The New England Journal of Medicine|October 19, 2022
Anti-BDCA2 Antibody for Cutaneous Lupus ErythematosusAntonios Psarras, Edward M Vital
Nature Reviews. Rheumatology|September 13, 2022
Emerging concepts of type I interferons in SLE pathogenesis and therapyAntonios Psarras, Miriam Wittmann, Edward M Vital
Current Opinion in Rheumatology|June 30, 2017
Musculoskeletal manifestations of systemic lupus erythmatosusKhaled Mahmoud, Ahmed Zayat, Edward M Vital
Rheumatology (Oxford, England)|April 12, 2012
Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosusEdward M Vital, Shouvik Dass, Paul Emery
Expert Opinion on Pharmacotherapy|December 8, 2006
Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritisShouvik Dass, Edward M Vital, Paul Emery
Pageof 12